42 related articles for article (PubMed ID: 12081632)
1. Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review.
Cheng Y; Zhang Y; Zhang Y; Liu M; Zhao L
Eur J Clin Pharmacol; 2024 Jul; 80(7):965-982. PubMed ID: 38498098
[TBL] [Abstract][Full Text] [Related]
2. External Evaluation of Population Pharmacokinetic Models for High-Dose Methotrexate in Adult Patients with Hematological Tumors.
Chen S; Huang L; Huang W; Zheng Y; Shen L; Liu M; Chen W; Wu X
J Clin Pharmacol; 2024 Apr; 64(4):437-448. PubMed ID: 38081138
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer: insights in disease and influence of drug methotrexate.
Yang V; Gouveia MJ; Santos J; Koksch B; Amorim I; Gärtner F; Vale N
RSC Med Chem; 2020 Jun; 11(6):646-664. PubMed ID: 33479665
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients.
Arshad U; Taubert M; Seeger-Nukpezah T; Ullah S; Spindeldreier KC; Jaehde U; Hallek M; Fuhr U; Vehreschild JJ; Jakob C
BMC Cancer; 2021 Jun; 21(1):719. PubMed ID: 34147089
[TBL] [Abstract][Full Text] [Related]
5. Computational oncology--mathematical modelling of drug regimens for precision medicine.
Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
7. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.
Dombrowsky E; Jayaraman B; Narayan M; Barrett JS
Ther Drug Monit; 2011 Feb; 33(1):99-107. PubMed ID: 21192315
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
[TBL] [Abstract][Full Text] [Related]
9. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy.
Barrett JS; Mondick JT; Narayan M; Vijayakumar K; Vijayakumar S
BMC Med Inform Decis Mak; 2008 Jan; 8():6. PubMed ID: 18226244
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.
Cohen IJ
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1057-1065. PubMed ID: 28455583
[TBL] [Abstract][Full Text] [Related]
12. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
Cohen IJ
Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
[TBL] [Abstract][Full Text] [Related]
13. Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer.
Monjanel-Mouterde S; Lejeune C; Ciccolini J; Merite N; Hadjaj D; Bonnier P; Piana P; Durand A
J Clin Pharm Ther; 2002 Jun; 27(3):189-95. PubMed ID: 12081632
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
[TBL] [Abstract][Full Text] [Related]
15. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
